>Mercado de bronquiectasias en Asia-Pacífico, por tipo de enfermedad (bronquiectasias por fibrosis quística y bronquiectasias sin fibrosis quística), gravedad (leve a moderada y moderada a grave), tipo (diagnóstico y tratamiento), tipo de medicamento (de marca y genéricos), vía de administración (oral, parenteral e inhalación), usuario final (hospitales, clínicas, atención médica domiciliaria y otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros), país (Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam y resto de Asia-Pacífico), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado: mercado de bronquiectasias en Asia y el Pacífico
Se espera que el mercado de bronquiectasias de Asia y el Pacífico gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 6,5% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 186,19 millones para 2028. El avance tecnológico para las pruebas de enfermedades y el aumento del número de fumadores y el consumo de alcohol son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
La bronquiectasia incluye características tales como la creciente necesidad de un producto seguro y eficaz que tendrá un impacto en el lanzamiento de nuevos productos por parte de los fabricantes al mercado, lo que aumentará su demanda, así como el aumento de la inversión en investigación y desarrollo que conduce al crecimiento del mercado. Actualmente, se están llevando a cabo varios estudios de investigación que se espera que creen una ventaja competitiva para que los fabricantes desarrollen productos nuevos e innovadores para la bronquiectasia, lo que se espera que brinde varias otras oportunidades en el mercado de la bronquiectasia. Sin embargo, se espera que los retiros de productos y las complicaciones en el tratamiento de la bronquiectasia limiten el crecimiento del mercado en el período de pronóstico.
La bronquiectasia es una enfermedad que daña las vías respiratorias de los pulmones, es decir, se produce una infección e inflamación en el lugar por donde entra y sale el aire. La mucosidad se acumula en las vías respiratorias, que se obstruyen y las bacterias comienzan a crecer en esa región, lo que provoca la bronquiectasia. Cuando esta mucosidad se acumula en las vías respiratorias y no se diagnostica ni se trata a tiempo, puede causar daños a los pulmones. Esta enfermedad se da principalmente en la población femenina y en los Estados Unidos se ha registrado que los niños con tos ferina suelen tener bronquiectasia.
La bronquiectasia puede ser congénita o adquirida. La adquirida se presenta principalmente en bebés y niños, mientras que la congénita se presenta en adultos. La fibrosis quística , los trastornos de inmunodeficiencia, la aspergilosis broncopulmonar alérgica y la discinesia ciliar primaria son algunos de los factores de riesgo de la bronquiectasia. Los médicos recomiendan principalmente antibióticos y terapias con oxígeno y los pacientes deben vivir con la enfermedad, ya que no existe una cura permanente para ella.
El informe de mercado de Bronquiectasias proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado , aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, comuníquese con nosotros para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de la bronquiectasia en Asia y el Pacífico
El mercado de la bronquiectasia está segmentado en función del tipo de enfermedad, la gravedad, el tipo, el tipo de fármaco, la vía de administración, el usuario final y el canal de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- Según el tipo de enfermedad, el mercado de la bronquiectasia se segmenta en bronquiectasias no relacionadas con fibrosis quística y bronquiectasias relacionadas con fibrosis quística. En 2021, se espera que la bronquiectasia no relacionada con fibrosis quística domine el mercado de la bronquiectasia, ya que es la forma más común de bronquiectasia que, según se informa, afecta a la mayoría de las mujeres y la población adulta.
- En función de la gravedad, el mercado de la bronquiectasia se segmenta en leve a moderada y moderada a grave. En 2021, se espera que el segmento leve a moderado domine el mercado de la bronquiectasia porque la bronquiectasia es un trastorno respiratorio progresivo que se caracteriza por vías respiratorias anormalmente dilatadas, producción excesiva de esputo e infecciones pulmonares recurrentes, entre otros síntomas que pueden tratarse con nuevos medicamentos y otras terapias.
- Según el tipo, el mercado de la bronquiectasia se segmenta en tratamiento y diagnóstico. En 2021, se espera que el segmento de tratamiento domine el mercado de la bronquiectasia porque la bronquiectasia es una enfermedad crónica a largo plazo y la población de pacientes afectados depende en gran medida de los medicamentos para llevar una vida saludable.
- Según el tipo de medicamento, el mercado de la bronquiectasia se segmenta en medicamentos de marca y genéricos . En 2021, se espera que el segmento de marca domine el mercado de la bronquiectasia, ya que la mayoría de las empresas se dedican a la fabricación de medicamentos de marca. Además, la creciente demanda de productos seguros aumenta la demanda de medicamentos de marca entre la población de pacientes.
- Según la vía de administración, el mercado de la bronquiectasia se segmenta en oral, parenteral e inhalatoria. En 2021, se espera que el segmento de inhalación domine el mercado de la bronquiectasia porque la bronquiectasia es una enfermedad inflamatoria asociada a los pulmones que se puede tratar rápidamente con medicamentos que se dirigen directamente a las vías respiratorias pulmonares.
- En función del usuario final, el mercado de la bronquiectasia se segmenta en hospitales , clínicas, atención médica domiciliaria y otros. En 2021, el segmento de hospitales domina el mercado de la bronquiectasia porque los hospitales cuentan con herramientas de diagnóstico avanzadas que se utilizan para un diagnóstico preciso de la bronquiectasia. Además, los profesionales capacitados en los hospitales permiten una administración eficaz de medicamentos por vía intravenosa, lo que actúa como otro factor que impulsa el crecimiento del mercado.
- Según el canal de distribución, el mercado de la bronquiectasia se segmenta en farmacias hospitalarias, farmacias minoristas y farmacias en línea. En 2021, se espera que las farmacias hospitalarias dominen el mercado de la bronquiectasia, ya que cuentan con una amplia gama de productos según las necesidades y la demanda de los pacientes.
Análisis del mercado de bronquiectasias a nivel de país
Se analiza el mercado de bronquiectasias y se proporciona información sobre el tamaño del mercado en función del tipo de enfermedad, la gravedad, el tipo, el tipo de medicamento, la vía de administración, el usuario final y el canal de distribución.
Los países cubiertos en el informe del mercado de bronquiectasias son Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam y el resto de Asia-Pacífico.
Se espera que el segmento de tratamiento en la región de Asia y el Pacífico crezca a la tasa más alta en el período de pronóstico de 2021 a 2028 porque la bronquiectasia es una enfermedad de por vida y requiere un tratamiento continuo. El costo general del tratamiento de la bronquiectasia es bastante alto y ahora se considera en algunas políticas de reembolso. Japón lidera el crecimiento del mercado de Asia y el Pacífico y el segmento de tratamiento domina en este país debido al avance tecnológico para el diagnóstico y tratamiento de enfermedades respiratorias.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
Los avances tecnológicos en el estudio de enfermedades y el aumento de la investigación sobre la enfermedad de la bronquiectasia están impulsando el crecimiento del mercado de la bronquiectasia
El mercado de la bronquiectasia también le proporciona un análisis detallado del mercado para cada país, el crecimiento de la industria de la bronquiectasia con las ventas de medicamentos para la bronquiectasia, el impacto del avance en la tecnología de la bronquiectasia y los cambios en los escenarios regulatorios con su apoyo al mercado de la bronquiectasia. Los datos están disponibles para el período histórico de 2011 a 2019.
Análisis del panorama competitivo y de la cuota de mercado de la bronquiectasia
El panorama competitivo del mercado de la bronquiectasia proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de la bronquiectasia.
Las principales compañías que se dedican al tratamiento de la bronquiectasia son Abbott, HERSILL, Inogen, Inc., Boehringer Ingelheim International GmbH, Medline Industries, Inc, Ache Laboratories Farmaceuticos SA, Janssen Pharmaceuticals, Inc. (una subsidiaria de Johnson & Johnson Services, Inc.), GlaxoSmithKline plc., AstraZeneca, Pfizer Inc., Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Bayer AG, Dr. Reddy's Laboratories Ltd., Viatris Inc. y Cipla Inc., entre otras.
Muchos lanzamientos de productos y acuerdos también son iniciados por empresas de todo el mundo, lo que también está acelerando el mercado de la bronquiectasia.
- En diciembre de 2018, AstraZeneca recibió la aprobación para Bevespi Aerosphere (fumarato de glicopirronio/formoterol), indicado para el tratamiento de los síntomas graves asociados a la EPOC. Este producto ya había recibido la aprobación de las autoridades regulatorias de Canadá, Estados Unidos, Australia, Taiwán y Turquía. Esta nueva aprobación mejoró las ventas del producto, lo que tuvo un impacto positivo en los ingresos de la empresa.
- En febrero de 2018, GlaxoSmithKline plc. lanzó Flunase en Japón. Flunase es el primer tratamiento a base de propionato de fluticasona lanzado en Japón y está indicado para aliviar los síntomas inflamatorios asociados a problemas respiratorios. Este lanzamiento de producto permitió a la empresa satisfacer la demanda no satisfecha de los pacientes que sufren bronquiectasia en Japón e impulsó los ingresos de la empresa mediante un aumento positivo de las ventas de productos.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias del actor del mercado están mejorando el mercado de la empresa en el mercado de la bronquiectasia, lo que también proporciona el beneficio para que la organización mejore su oferta para la bronquiectasia.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC BRONCHIECTASIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET DRUGS TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 ASIA PACIFIC BRONCHIECTASIS MARKET: LAWS AND REGULATIONS
6 EPIDEMIOLOGY
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS
7.1.2 GROWING GERIATRIC POPULATION
7.1.3 RISING NUMBER OF SMOKERS AND CONSUMPTION OF ALCOHOL
7.1.4 TECHNOLOGICAL ADVANCEMENT FOR DISEASE TESTING
7.1.5 GROWING DIAGNOSTIC RATE
7.2 RESTRAINTS
7.2.1 HIGH COST OF DIAGNOSTIC TOOLS
7.2.2 PRODUCT RECALLS
7.2.3 INAPPROPRIATE REIMBURSEMENT POLICIES
7.3 OPPORTUNITIES
7.3.1 RISING AWARENESS FOR PREVENTION OF BRONCHIECTASIS IN PRIMARY AND SECONDARY CARE
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 INCREASE IN RESEARCH REGARDING THE BRONCHIECTASIS DISEASE
7.3.4 AVAILABILITY OF GENERIC DRUGS IN UNDERDEVELOPED AND DEVELOPING COUNTRIES
7.4 CHALLENGES
7.4.1 COMPLICATIONS IN THE TREATMENT OF BRONCHIECTASIS
7.4.2 LACK OF SKILLED PROFESSIONALS
7.4.3 DIAGNOSITIC CHALLENGES
8 IMPACT OF COVID-19
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 NON-CF BRONCHIECTASIS
9.3 CF BRONCHIECTASIS
10 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY
10.1 OVERVIEW
10.2 MILD TO MODERATE
10.3 MODERATE TO SEVERE
11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE
11.1 OVERVIEW
11.2 TREATMENT
11.2.1 ANTIBIOTICS
11.2.1.1 MACROLIDE
11.2.1.1.1 AZITHROMYCIN
11.2.1.1.2 CLARITHROMYCIN
11.2.1.1.3 OTHERS
11.2.1.2 AMOXICILLIN
11.2.1.3 CEPHALOSPORIN
11.2.1.3.1 SECOND-GENERATION CEPHALOSPORIN
11.2.1.3.2 THIRD-GENERATION CEPHALOSPORIN
11.2.1.4 AMINOGLYCOSIDE
11.2.1.4.1 GENTAMICIN
11.2.1.4.2 TOBRAMYCIN
11.2.1.5 FLUOROQUINOLONE
11.2.1.6 TETRACYCLINS
11.2.1.7 TRIMETHOPRIM-SULFAMETHOXAZOLE
11.2.1.8 COMBINATION THERAPY
11.2.2 CORTICOSTEROIDS
11.2.2.1 BUDESONIDE
11.2.2.2 FLUTICASONE
11.2.2.3 MOMETASONE
11.2.2.4 FLUNISOLIDE
11.2.2.5 OTHERS
11.2.3 BRONCHODILATORS
11.2.3.1 LONG-ACTING BRONCHODILATORS
11.2.3.1.1 FORMOTEROL
11.2.3.1.2 TIOTROPIUM
11.2.3.1.3 SALMETEROL
11.2.3.1.4 OTHERS
11.2.3.2 SHORT-ACTING BRONCHODILATORS
11.2.3.2.1 ALBUTEROL
11.2.3.2.2 LEVALBUTEROL
11.2.3.2.3 OTHERS
11.2.4 MUCUS THINNING MEDICINE
11.2.4.1 CARBOCISTEINE
11.2.4.2 BROMHEXINE
11.2.4.3 OTHERS
11.2.5 AIRWAY CLEARANCE DEVICES
11.2.5.1 OSCILLATING POSITIVE EXPIRATORY PRESSURE (PEP)
11.2.5.2 INTRAPULMONARY PERCUSSIVE VENTILATION (IPV)
11.2.5.3 POSTURAL DRAINAGE
11.2.5.4 OTHERS
11.2.6 OXYGEN THERAPY
11.2.6.1 OXYGEN CONCENTRATORS
11.2.6.2 COMPRESSED GAS OXYGEN
11.2.6.3 LIQUID OXYGEN
11.2.7 SURGERY
11.2.7.1 BRONCHOSCOPY
11.2.7.2 LUNG TRANSPLANT
11.2.8 OTHERS
11.3 DIAGNOSIS
11.3.1 CHEST CT SCAN
11.3.2 SPUTUM TEST
11.3.3 PULMONARY FUNCTION TEST
11.3.4 X-RAY
11.3.5 OTHERS
12 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 BRANDED
12.3 GENERICS
13 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 INHALATION
13.3 ORAL
13.3.1 TABLETS
13.3.2 CAPSULES
13.3.3 OTHERS
13.4 PARENTERAL
13.4.1 INTRAVENOUS
13.4.2 SUBCUTANEOUS
13.4.3 OTHERS
14 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS
15 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 HOSPITAL PHARMACY
15.3 RETAIL PHARMACY
15.4 ONLINE PHARMACY
15.5 OTHERS
16 ASIA PACIFIC BRONCHIECTASIS MARKET BY GEOGRAPHY
16.1 OVERVIEW
16.2 ASIA-PACIFIC
16.2.1 JAPAN
16.2.2 CHINA
16.2.3 INDIA
16.2.4 AUSTRALIA
16.2.5 SOUTH KOREA
16.2.6 SINGAPORE
16.2.7 MALAYSIA
16.2.8 THAILAND
16.2.9 INDONESIA
16.2.10 PHILIPPINES
16.2.11 VIETNAM
16.2.12 REST OF ASIA-PACIFIC
17 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
18 SWOT
19 COMPANY PROFILES
19.1 ASTRAZENECA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 GLAXOSMITHKLINE PLC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 TEVA PHARMACEUTICAL USA INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 MERCK SHARP & DOHME CORP. (A SUBSIDIARY OF MERCK & CO., INC.)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 NOVARTIS AG
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 ABBOTT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 ACHE LABORATORIES FARMACEUTICOS S.A.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 BAYER AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 CIPLA INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 COVIS PHARMA
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 DR. REDDY’S LABORATORIES LTD.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 ELECTROMED, INC.
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENTS
19.14 HERSILL
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 HOME OXYGEN COMPANY
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 HORIZON THERAPEUTICS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 INOGEN, INC.
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 MEDLINE INDUSTRIES, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 SUNOVION PHARMACEUTICALS INC. (A SUBSIDIARY OF SUMITOMO DAINIPPON PHARMA CO., LTD.)
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENTS
19.22 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENTS
19.23 TRUEDELL MEDICAL INTERNATIONAL
19.23.1 COMPANY SNAPSHOT
19.23.2 PRODUCT PORTFOLIO
19.23.3 RECENT DEVELOPMENTS
19.24 VIATRIS INC.
19.24.1 COMPANY SNAPSHOT
19.24.2 PRODUCT PORTFOLIO
19.24.3 RECENT DEVELOPMENTS
19.25 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)
19.25.1 COMPANY SNAPSHOT
19.25.2 REVENUE ANALYSIS
19.25.3 PRODUCT PORTFOLIO
19.25.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tablas
LIST OF TABLES
TABLE 1 ASIA PACIFIC BRONCHIECTASIS MARKET, PIPELINE ANALYSIS
TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS
TABLE 3 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 4 THE PRICE OF X-RAY MACHINE
TABLE 5 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA PACIFIC NON-CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA PACIFIC CF BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 9 ASIA PACIFIC MILD TO MODERATE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA PACIFIC MODERATE TO SEVERE BRONCHIECTASIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 13 ASIA PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 ASIA PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 ASIA PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 ASIA PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 ASIA PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 ASIA PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 ASIA PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 ASIA PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 ASIA PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 ASIA PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 ASIA PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 24 ASIA PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 25 ASIA PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 ASIA PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA PACIFIC BRANDED IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 ASIA PACIFIC GENERICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 ASIA PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 32 ASIA PACIFIC INHALATION IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 ASIA PACIFIC ORAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 ASIA PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 ASIA PACIFIC PARENTERAL IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 ASIA PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 37 ASIA PACIFIC BRONCHIECTASIS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 ASIA PACIFIC HOSPITALS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 ASIA PACIFIC CLINICS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 ASIA PACIFIC HOME HEALTHCARE IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 ASIA PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 ASIA PACIFIC HOSPITAL PHARMACY IN BRONCHIECTASIS MARKET, REGION, 2019-2028 (USD MILLION)
TABLE 44 ASIA PACIFIC RETAIL PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 ASIA PACIFIC ONLINE PHARMACY IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 ASIA PACIFIC OTHERS IN BRONCHIECTASIS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC BRONCHIECTASIS MARKET, BY REGION , 2021-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 72 JAPAN BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 73 JAPAN BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 74 JAPAN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 JAPAN TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 JAPAN TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 JAPAN TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 JAPAN TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 79 JAPAN TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 80 JAPAN TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 81 JAPAN TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 JAPAN TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 JAPAN TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 JAPAN TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 85 JAPAN TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 JAPAN TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 JAPAN TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 JAPAN DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 JAPAN BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 90 JAPAN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 JAPAN ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 92 JAPAN PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 93 JAPAN BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 94 JAPAN BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 CHINA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 96 CHINA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 97 CHINA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 CHINA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 99 CHINA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 100 CHINA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 101 CHINA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CHINA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 CHINA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 CHINA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 CHINA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 106 CHINA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 CHINA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 CHINA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 CHINA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 CHINA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 CHINA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 CHINA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 113 CHINA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 114 CHINA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 115 CHINA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 116 CHINA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 117 CHINA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 118 INDIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 119 INDIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 120 INDIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 121 INDIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 INDIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 INDIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 124 INDIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 125 INDIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 126 INDIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 INDIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 INDIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 INDIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 INDIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 INDIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 INDIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 INDIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 INDIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 INDIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 136 INDIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 INDIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 INDIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 139 INDIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 140 INDIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 AUSTRALIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 142 AUSTRALIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 143 AUSTRALIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 144 AUSTRALIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 145 AUSTRALIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 146 AUSTRALIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 AUSTRALIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 AUSTRALIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 AUSTRALIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 AUSTRALIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 AUSTRALIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 AUSTRALIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 AUSTRALIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 AUSTRALIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 AUSTRALIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 AUSTRALIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 AUSTRALIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 AUSTRALIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 159 AUSTRALIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 AUSTRALIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 AUSTRALIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 AUSTRALIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 163 AUSTRALIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 SOUTH KOREAT BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 166 SOUTH KOREA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SOUTH KOREA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 SOUTH KOREA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 SOUTH KOREA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 SOUTH KOREA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 SOUTH KOREA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 SOUTH KOREA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 SOUTH KOREA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 SOUTH KOREA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 SOUTH KOREA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 SOUTH KOREA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 SOUTH KOREA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 SOUTH KOREA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 179 SOUTH KOREA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 180 SOUTH KOREA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 181 SOUTH KOREA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 182 SOUTH KOREA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 SOUTH KOREA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 184 SOUTH KOREA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 185 SOUTH KOREA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 186 SOUTH KOREA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 187 SINGAPORE BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 188 SINGAPORE BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 189 SINGAPORE BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 190 SINGAPORE TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 191 SINGAPORE TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 192 SINGAPORE TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 193 SINGAPORE TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 194 SINGAPORE TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 195 SINGAPORE TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SINGAPORE TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 197 SINGAPORE TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 198 SINGAPORE TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 199 SINGAPORE TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 200 SINGAPORE TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 201 SINGAPORE TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 202 SINGAPORE TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 203 SINGAPORE DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 204 SINGAPORE BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 205 SINGAPORE BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 206 SINGAPORE ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 207 SINGAPORE PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 SINGAPORE BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 209 SINGAPORE BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 210 MALAYSIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 211 MALAYSIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 212 MALAYSIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 213 MALAYSIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 MALAYSIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 215 MALAYSIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 216 MALAYSIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 217 MALAYSIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 218 MALAYSIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 219 MALAYSIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 220 MALAYSIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 221 MALAYSIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 222 MALAYSIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 223 MALAYSIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 224 MALAYSIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 MALAYSIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 226 MALAYSIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 227 MALAYSIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 228 MALAYSIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 MALAYSIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 MALAYSIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 231 MALAYSIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 232 MALAYSIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 233 THAILAND BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 234 THAILAND BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 235 THAILAND BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 236 THAILAND TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 237 THAILAND TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 238 THAILAND TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 239 THAILAND TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 240 THAILAND TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 241 THAILAND TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 242 THAILAND TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 THAILAND TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 244 THAILAND TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 245 THAILAND TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 246 THAILAND TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 247 THAILAND TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 248 THAILAND TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 249 THAILAND DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 250 THAILAND BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 251 THAILAND BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 252 THAILAND ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 253 THAILAND PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 254 THAILAND BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 255 THAILAND BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 256 INDONESIA BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 257 INDONESIA BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 258 INDONESIA BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 259 INDONESIA TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 260 INDONESIA TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 INDONESIA TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 262 INDONESIA TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 263 INDONESIA TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 264 INDONESIA TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 265 INDONESIA TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 266 INDONESIA TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 267 INDONESIA TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 268 INDONESIA TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 269 INDONESIA TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 INDONESIA TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 271 INDONESIA TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 272 INDONESIA DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 273 INDONESIA BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 274 INDONESIA BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 INDONESIA ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 276 INDONESIA PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 277 INDONESIA BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 278 INDONESIA BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 279 PHILIPPINES BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 280 PHILIPPINES BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 281 PHILIPPINES BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 282 PHILIPPINES TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 283 PHILIPPINES TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 284 PHILIPPINES TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 285 PHILIPPINES TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 286 PHILIPPINES TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 287 PHILIPPINES TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 288 PHILIPPINES TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 289 PHILIPPINES TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 PHILIPPINES TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 291 PHILIPPINES TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 292 PHILIPPINES TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 293 PHILIPPINES TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 294 PHILIPPINES TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 295 PHILIPPINES DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 296 PHILIPPINES BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 297 PHILIPPINES BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 298 PHILIPPINES ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 299 PHILIPPINES PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 300 PHILIPPINES BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 301 PHILIPPINES BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 302 VIETNAM BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 303 VIETNAM BRONCHIECTASIS MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 304 VIETNAM BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 305 VIETNAM TREATMENT IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 306 VIETNAM TREATMENT BY ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 307 VIETNAM TREATMENT BY MACROLIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 VIETNAM TREATMENT BY CEPHALOSPORIN ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 309 VIETNAM TREATMENT BY AMINOGLYCOSIDE ANTIBIOTICS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 310 VIETNAM TREATMENT BY CORTICOSTEROIDS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 311 VIETNAM TREATMENT BY BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 312 VIETNAM TREATMENT BY LONG-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 313 VIETNAM TREATMENT BY SHORT-ACTING BRONCHODILATORS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 314 VIETNAM TREATMENT BY MUCUS THINNING MEDICINE IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 315 VIETNAM TREATMENT BY AIRWAY CLEARANCE DEVICES IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 316 VIETNAM TREATMENT BY OXYGEN THERAPY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 317 VIETNAM TREATMENT BY SURGERY IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 318 VIETNAM DIAGNOSIS IN BRONCHIECTASIS MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 319 VIETNAM BRONCHIECTASIS MARKET, BY DRUGS TYPE, 2019-2028 (USD MILLION)
TABLE 320 VIETNAM BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 321 VIETNAM ORAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 322 VIETNAM PARENTERAL ADMINISTRATION IN BRONCHIECTASIS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 323 VIETNAM BRONCHIECTASIS MARKET, BY END USERNEL, 2019-2028 (USD MILLION)
TABLE 324 VIETNAM BRONCHIECTASIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 325 REST OF ASIA-PACIFIC BRONCHIECTASIS MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
Lista de figuras
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC BRONCHIECTASIS MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC BRONCHIECTASIS MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC BRONCHIECTASIS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC BRONCHIECTASIS MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA PACIFIC BRONCHIECTASIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA PACIFIC BRONCHIECTASIS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA PACIFIC BRONCHIECTASIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC BRONCHIECTASIS MARKET: MARKET DRUGS TYPE COVERAGE GRID
FIGURE 11 ASIA PACIFIC BRONCHIECTASIS MARKET: SEGMENTATION
FIGURE 12 RISING PATIENT POPULATION SUFFERING FROM BRONCHIECTASIS IS DRIVING THE ASIA PACIFIC BRONCHIECTASIS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 NON-CF BRONCHIECTASIS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BRONCHIECTASIS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA PACIFIC BRONCHIECTASIS MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 PREVALENCE OF BRONCHIECTASIS BY AGE IN KOREA POPULATION (2019)
FIGURE 17 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 18 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2021
FIGURE 19 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, 2019-2028 (USD MILLION)
FIGURE 20 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, CAGR (2021-2028)
FIGURE 21 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 22 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2021
FIGURE 23 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, 2019-2028 (USD MILLION)
FIGURE 24 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, CAGR(2021-2028)
FIGURE 25 ASIA PACIFIC BRONCHIECTASIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 26 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2021
FIGURE 27 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 28 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 29 ASIA PACIFIC BRONCHIECTASIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2021
FIGURE 31 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, 2019-2028 (USD MILLION)
FIGURE 32 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, CAGR (2021-2028)
FIGURE 33 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 34 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 35 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
FIGURE 36 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 37 ASIA PACIFIC BRONCHIECTASIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 38 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2021
FIGURE 39 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 40 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 41 ASIA PACIFIC BRONCHIECTASIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 42 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 43 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 44 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 45 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 46 ASIA PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 47 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 48 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 49 ASIA PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 50 ASIA PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 51 ASIA-PACIFIC BRONCHIECTASIS MARKET: SNAPSHOT (2020)
FIGURE 52 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020)
FIGURE 53 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 54 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 55 ASIA-PACIFIC BRONCHIECTASIS MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 56 ASIA PACIFIC BRONCHIECTASIS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
